The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony Study-Reference-Cited by-同舟云学术

The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony Study

Published:2009-05-15 Issue:9 Volume:87 Page:1360-1366
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Ekberg Henrik,Mamelok Richard D.,Pearson Thomas C.,Vincenti Flavio,Tedesco-Silva Hélio,Daloze Pierre

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference10 articles.

1. Reduced exposure to calcineurin inhibitors in renal transplantation.;Ekberg;N Engl J Med,2007

2. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation.;Ekberg;Scand J Immunol,2003

3. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.;Kuypers;Clin Transplant,2003

4. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR study.;Ekberg;Am J Transplant,2006

5. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation.;Grinyo;Am J Transplant,2004

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the evidence for genotype‐informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review;British Journal of Clinical Pharmacology;2024-08-15

2. Bayesian optimization of tacrolimus exposure in stable kidney transplant patients;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-07-23

3. Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation;BMC Nephrology;2023-05-08

4. Impact of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation;British Journal of Clinical Pharmacology;2023-02

5. The Appropriately Designed TDM Clinical Trial: Endpoints, Pitfalls, and Perspectives;Therapeutic Drug Monitoring;2023-02